Publications scientifiques Bordet

Publications scientifiques Bordet

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) VANDERLINDEN BRUNO
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) KARFIS IOANNIS
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) FLAMEN PATRICK
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) MARIN GWENNAELLE
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) PICCART MARTINE
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) VINCENT DELPHINE
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) MAJJAJ SAMIRA
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) SOTIRIOU CHRISTOS
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

  • Auteurs Kouvaraki M, Zerdes I, Sifakis EG, Sarafidis M, Matikas A, Tzoras E, Kjällquist U, Stathopoulou K, Lövrot J, Alkodsi A, Hartman J, Sotiriou C, Richard F, Hatschek T, Herold N, Bergh J, Rassidakis GZ, Foukakis T
  • Auteurs (entité) SOTIRIOU CHRISTOS
  • Revue Int J Cancer
  • Date de publication 2024-12
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Publications scientifiques d'Erasmus
Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Publications scientifiques de l'Hôpital pour enfants Reine Fabiola
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Publications scientifiques de Jules Bordet